The LiBBY trial tested a purified THC-plus-CBD oil for agitation in hospice-eligible late-stage dementia, not in mild cognitive impairment. For people with MCI, it does not test or support using THC or CBD to treat memory or thinking changes.
MCI means early thinking changes with daily function largely preserved. Agitation here means restlessness, shouting, or physical behaviors that distress patients and caregivers in advanced dementia. LiBBY compared active oil with placebo under home-visit supervision.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who joined LiBBY
- How much did agitation fall
- What did safety show
- Why LiBBY does not cover MCI
- What should people with MCI discuss instead
Who joined LiBBY
Georgetown University School of Medicine reports LiBBY enrolled 120 people with Alzheimer's or other dementia who were hospice-eligible with clinically significant agitation across 10 U.S. sites in its trial summary.
Home visits supported participation for this frail group. This population differs sharply from MCI readers: The active group received a fixed twice-daily oral oil. The comparison group received matching placebo for 12 weeks.
- hospice-eligible severe dementia with significant agitation
- supervised study drug or matching placebo with home visits
- not people with MCI living independently
How much did agitation fall
MIMS, summarizing Mintzer's AAIC presentation, reports CMAI agitation scores fell 10.61 points on THC and CBD versus 4.35 on placebo at 2 weeks in its presentation summary. CMAI is a standard agitation scale. The added reduction was 6.27 points, p=0.0004.
The gap appeared early, at two weeks. It measures calmer behavior, not better memory or daily function. NeurologyLive coverage also notes higher clinician-rated overall improvement with treatment.
What did safety show
NeurologyLive reports similar overall adverse events, 46.7% versus 42.4%, but more serious events on THC and CBD, 23.3% versus 11.9%, in its trial coverage. Serious events included infections and deaths in this end-of-life group.
High background illness is expected in hospice-eligible dementia. Serious events still matter when weighing calm against harm. Families should not read similar total events as equal risk.
Why LiBBY does not cover MCI
The Alzheimer's Association describes MCI as an early stage with largely preserved daily function, unlike LiBBY's hospice-eligible severe dementia population, in its MCI information. LiBBY therefore does not test THC and CBD for MCI. Its results also apply only to the supervised purified product, not dispensary cannabis.
Trying a dispensary oil is not the same dose, purity, or monitoring. People with MCI have different causes of restlessness and different risks. Sedation, falls, drug interactions, and impaired driving pose direct threats to independence.
What should people with MCI discuss instead
Track new restlessness, sleep loss, pain, mood change, and medication changes. Many triggers are treatable without sedation.
Bring that record to primary care or dementia care. Ask focused questions at the visit: Bring a two-week note of sleep, mood changes, and new restlessness to that visit.
- what may explain my sleep or mood change
- which drugs, alcohol, or supplements could worsen thinking or agitation
- what daily routines, activity, and support reduce distress
- when to seek urgent evaluation for sudden confusion or aggression
You Might Also Like
- LatAm-FINGERS Lifestyle Coaching Findings Across 11 Countries in 2026: What People With Mild Cognitive Impairment Can Track Without Self-Diagnosing
- UAS-CLEAR Dementia Care Research Data Priorities in 2026: Who Was Studied and Who Was Not for People With Mild Cognitive Impairment
- What Is the Difference Between Mild Cognitive Impairment and Parkinson’s Disease Dementia?
